User profiles for Robert S. Wallis

Robert S. Wallis, MD, FIDSA

CSO, Aurum Institute; Prof Medicine, CWRU & Vanderbilt
Verified email at po.cwru.edu
Cited by 15849

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

RS Wallis, M Pai, D Menzies, TM Doherty, G Walzl… - The lancet, 2010 - thelancet.com
Human infection with Mycobacterium tuberculosis can progress to active disease, be
contained as latent infection, or be eradicated by the host response. Tuberculosis diagnostics …

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

…, B Hellmich, R Groves, S Schreiber, RS Wallis… - 2010 - Eur Respiratory Soc
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have
become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid …

[HTML][HTML] High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

…, C Manyama, B Mtafya, K Reither, RS Wallis… - The Lancet infectious …, 2017 - thelancet.com
Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

[HTML][HTML] Host-directed immunotherapy of viral and bacterial infections: past, present and future

RS Wallis, A O'Garra, A Sher, A Wack - Nature Reviews Immunology, 2023 - nature.com
The advent of COVID-19 and the persistent threat of infectious diseases such as tuberculosis,
malaria, influenza and HIV/AIDS remind us of the marked impact that infections continue to …

Depressed T-cell interferon-γ responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy

…, SK Schwander, S Robertson, RS Wallis… - Journal of Infectious …, 1999 - academic.oup.com
Immunological and clinical profiles were evaluated in 2 groups: human immunodeficiency
virus (HIV)—uninfected and HIV-infected patients, with newly diagnosed pulmonary …

Advancing host-directed therapy for tuberculosis

RS Wallis, R Hafner - Nature Reviews Immunology, 2015 - nature.com
Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection.
Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment …

Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

RS Wallis, M Maeurer, P Mwaba, J Chakaya… - The Lancet infectious …, 2016 - thelancet.com
Tuberculosis is the leading infectious cause of death worldwide, with 9·6 million cases and 1·5
million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

RS Wallis - The Lancet infectious diseases, 2008 - thelancet.com
Our understanding of the infection risks presented by tumour necrosis factor (TNF) antagonists
has continued to evolve in the 10 years since these drugs were first introduced. Several …

[HTML][HTML] Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

A Zumla, M Rao, RS Wallis, SHE Kaufmann… - The Lancet Infectious …, 2016 - thelancet.com
Despite extensive global efforts in the fight against killer infectious diseases, they still cause
one in four deaths worldwide and are important causes of long-term functional disability …

Tuberculosis biomarkers discovery: developments, needs, and challenges

RS Wallis, P Kim, S Cole, D Hanna… - The Lancet infectious …, 2013 - thelancet.com
Biomarkers are indispensable to the development of new tuberculosis therapeutics and
vaccines. The most robust biomarkers measure factors that are essential to the underlying …